Granulox®, launched in June 2012 as a Class III medical device in the EU, is a treatment that speeds healing in slow-healing wounds such as foot ulcers, leg ulcers, pressure sores and post-surgical wounds. The main ingredient is pure haemoglobin, which acts as an oxygen transporter from surrounding air to improve oxygen availability in the wound-bed and thus aid wound healing.
Chronic wounds commonly affect elderly and / or diabetic patients and are often caused by circulation problems or peripheral vascular disease which causes low levels of oxygen provision to the wound via the blood (hypoxia). Wound healing is supported by spraying a small amount of Granulox® onto the wound before application of standard (breathable) wound dressings. In a 13 week randomised controlled trial of slow healing leg ulcers, wounds were reduced in size by more than half when Granulox® was added to standard care, while patients on standard care alone had no significant improvement. Pain was also reduced, with 61% lower mean pain scores. A different 6-month study showed that more than 93% of patients with chronic lower leg and foot ulcers achieved wound healing within 6 months after often having suffered with chronic wounds for months or years.
Granulox® is available to the NHS in England and Wales and NHSScotland. Infirst is working on making Granulox available to selected international markets including the U.S.A.
In 2010, about 73,000 non-traumatic lower-limb amputations were performed in US adults aged 20 years or older with diagnosed diabetes